Pulse Biosciences Inc
6L8
Company Profile
Business description
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Contact
601 Brickell Key Drive
Suite 1080
MiamiFL33131
USAT: +1 510 906-4600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
75
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.00 | 9.10 | -0.10% |
| CAC 40 | 7,709.32 | 74.29 | 0.97% |
| DAX 40 | 24,192.50 | 268.14 | 1.12% |
| Dow JONES (US) | 43,968.64 | 224.48 | -0.51% |
| FTSE 100 | 9,100.77 | 63.54 | -0.69% |
| HKSE | 25,081.63 | 171.00 | 0.69% |
| NASDAQ | 21,242.70 | 73.27 | 0.35% |
| Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
| NZX 50 Index | 12,876.02 | 11.08 | -0.09% |
| S&P 500 | 6,340.00 | 5.06 | -0.08% |
| S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
| SSE Composite Index | 3,639.67 | 5.67 | 0.16% |